WillItSurvive
Medical technology and health companies · Japan

Medley Inc

medley.jp ↗

Japan platform running JobMedley (HR recruiting) and CLINICS/Pharms/Dentis (medical software)

Losing its protection
Assessed 30 July 2026 · Evidence as of 30 July 2026
The structural protection is eroding.
On the recordSince 30 July 2026 · Checkable from mid-August 2026 · Every call on the record Checkpoint: Q2 FY2026 earnings: check if HR-platform revenue stabilizes and operating profit turns positive
The call

Medley's medical software side is locked into Japan's regulated healthcare system, but its HR recruiting engine is losing margin to a 2025 incentive ban and AI-driven admin automation.

Medley runs two businesses: JobMedley, a job-matching platform for doctors and pharmacists in Japan, and a Medical Platform that provides software to clinics, pharmacies, and dental offices. The medical software side is genuinely hard to replace because it handles patient records, billing, and schedules in a way that fits Japanese rules, and 20,000 facilities already use it. But JobMedley, the cash machine, is getting squeezed: Japan banned signing bonuses (which patients and employers were paying to recruit), the company cut its sales forecast in half during 2025, and artificial intelligence now does the routine work of screening resumes and sending recruiter messages faster and cheaper than a human platform can. The company will probably survive, but investors won't get the growth they expected unless the Medical Platform business becomes profitable enough to make up for JobMedley's shrinking profits. The next earnings report will show whether JobMedley can bounce back or keeps sliding.

Why
01
AI pressure: Generic AI recruiting-automation tools (LLM-based resume screening and scouting bots). AI is automating the resume screening and scouting work JobMedley charges per-hire fees for, squeezing that margin layer. Could AI do the core job? Only partly.
02
Bigger players: Recruit Holdings. Recruit sold its doctor and pharmacist recruiting business to Medley in March 2026, retreating from the niche rather than attacking it. Could a giant copy it? Probably.
03
What protects it. 20,000+ facilities and 3M registered workers are wired into Medley's regulated, Japan-specific EHR and hiring systems, hard to rip out.
What would change this call
Medley's Q2 FY2026 earnings (mid-August 2026) show HR-platform revenue growth and operating profit turning positive. Would show the signing-bonus ban and AI compression are stabilizing rather than worsening.
Two consecutive quarters of operating profit recovery with no further guidance cuts. Would confirm execution is stabilizing and the platform model still compounds.
Medley AI Cloud shows measurable cross-sell revenue growth in Medical Platform segment reporting. Would show Medical Platform becoming a real profit engine, not just a cost offset.
Key numbers
  • FY2025 sales ¥36.79B, up 25.5% YoY (2025-12-31)
  • Q1 FY2026 operating loss of ¥61M (2026-03-31)
  • JobMedley used by 38% of target facilities in Japan (2026-01-01)
Named risks
  • JobMedley HR-platform revenue missed plan by ¥900M in FY2025, triggering a guidance cut. Severity: high
  • Generative AI commoditizing the recruitment-admin workflows JobMedley's fee model relies on. Severity: high
  • Regulatory ban on signing-bonus incentives (effective April 2025) restructured JobMedley's incentive economics. Severity: medium
  • Under-reporting of recruitment confirmations tied to incentive program, still ~4% as of October 2025. Severity: medium
  • Stock down 41-45% over trailing year as of July 2026, pressuring capital allocation and morale. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Recruit Holdingsgaining onRecruit sold its doctor/pharmacist recruitment business to Medley on March 27, 2026, exiting the niche
Generative AI tools (recruitment admin automation)losing toAI is compressing JobMedley's per-hire admin margin; CFO cited AI efficiency offsetting revenue miss on Nov 13, 2025
Domestic EHR/hospital-IT vendorscontestingCoexist alongside Medley's CLINICS/Pharms/Dentis in Japan's regulated medical platform space, per company disclosures dated 2025-08-31
Questions people ask
Is Medley in financial trouble?
Medley is not in acute financial trouble but has repeatedly missed its own targets: FY25 guidance from February 2025 called for 35.8% revenue growth and 14.3% EBITDA margin, while Q3 FY25 results in November 2025 came in at 31% revenue growth and only 10% EBITDA margin. That gap has driven the stock down roughly 35-38% over the trailing year as of July 2026, and TTM revenue stands at 38.84 billion yen with net income of 988 million yen (July 2026).
What is Medley's biggest risk right now?
The biggest documented risk is self-inflicted: repeated downward guidance revisions plus a subsidy-reporting compliance gap tied to employment retention hires, which have shaken investor confidence more than any competitor has. Watch whether Medley issues another guidance cut around its Q2 FY26 earnings in mid-August 2026, and whether the subsidy compliance gap falls below 1% by the end of 2026.
Who are Medley's biggest competitors?
M3, Inc. reaches over 90% of Japanese physicians through media but has not shipped a competing recruitment or EHR product in 15 years, and Recruit Group actually divested its Medical Career physician and pharmacist recruitment unit to Medley on March 27, 2026, consolidating rather than contesting Medley's space. No named rival is documented pulling customers away as of the July 2026 assessment.
Is Medley at risk from AI?
AI-native entrants Ubie and Layered are building voice-charting and documentation tools as of 2025-2026, but as of the July 2026 assessment neither has connected to Japan's claims reimbursement system, which is the sticky part of Medley's SaaS products like CLINICS. Medley's own SaaS tools create switching friction for clinics and staffing agencies that these AI-native tools have not yet overcome, and the company is responding by adding AI features into its own CLINICS and MALL products rather than losing ground.
Could a bigger company copy or crush Medley's business?
Giant-copy risk is rated possible rather than shipped in practice: M3, Inc. has the physician media reach to attempt it but has not launched a competing recruiting or EHR platform in the past 15 years. Recruit Group instead chose to sell its Medical Career unit to Medley on March 27, 2026, which widened Medley's lead rather than narrowing it.
How does Medley compare to others in its category on durability?
As of the July 2026 assessment, Medley's marketplace scale and embedded SaaS tools like CLINICS create switching friction for clinics and staffing agencies that competitors have not matched. M3, Inc. has over 90% physician media reach but has not shipped a competing recruitment or EHR product in 15 years, and Recruit Group chose to divest its Medical Career recruitment unit to Medley on March 27, 2026 rather than compete directly. The main soft spot is not competitive share loss but Medley's own repeated guidance misses and a subsidy-reporting compliance gap, which have weighed on investor confidence even as the underlying 440,000-facility marketplace position has held.
Timeline
  • 2026-07-01Medley announces Applied AI Developer role with total comp over ¥60 million
  • 2026-05-13Q1 FY2026 results: revenue ¥10.19B, operating loss ¥61M
  • 2026-03-27Medley takes over Recruit Medical Career's doctor and pharmacist recruitment business
  • 2026-01-01Kaigo-no-Honne nursing facility site integrated into Medley's Minkai platform
  • 2025-11-14Medley announces buyback of up to 4.8% of shares worth ¥3 billion
  • 2025-11-13Q3 FY2025 earnings: FY2025 guidance cut after ¥900M HR-platform revenue miss
  • 2025-09-01Medley AI Cloud launches with generative AI transcription and drafting features
  • 2025-04-01MHLW ban on signing-bonus style recruitment incentives takes effect
  • 2019-12-12Medley IPOs on TSE Mothers market
  • 2009-06-05Medley founded by CEO Kohei Takiguchi
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources